LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Speedy Cell Cycle Slows Stem Cell Differentiation

By LabMedica International staff writers
Posted on 28 Dec 2017
Image: A photomicrograph showing stem cells (red) and differentiating cells (green) (Photo courtesy of Cook Laboratory, University of North Carolina).
Image: A photomicrograph showing stem cells (red) and differentiating cells (green) (Photo courtesy of Cook Laboratory, University of North Carolina).
A team of cell biologists has found that the ability of pluripotent stem cells to remain in an undifferentiated state is linked to the length of time the cell spends in the G1 phase of cell division.

All dividing cells must first unwind their DNA so that it can be copied. To achieve this, cells load DNA-unwinding enzymes called helicases onto their DNA during the part of the cell cycle known as G1 phase. Cells must load enough helicase enzymes to ensure that their DNA is copied completely and in time. Stem cells divide faster than their specialized descendants, and have a much shorter G1 phase, as well. Yet these cells still manage to load enough helicases to copy their DNA. Little is known about how the amount, rate, and timing of helicase loading vary between cells that divide at different speeds.

Complete and robust human genome duplication requires loading minichromosome maintenance (MCM) helicase complexes at many DNA replication origins, an essential process termed origin licensing. Licensing is restricted to G1 phase of the cell cycle, but G1 length varies widely among cell types. Investigators at the University of North Carolina (Chapel Hill, USA) utilized single-cell flow cytometry to measure MCM loading rates in asynchronous populations of pluripotent and differentiated cells.

Results published in the November 17, 2017, online edition of the journal eLife revealed that pluripotent stem cells with naturally short G1 phases loaded MCM much faster than their isogenic differentiated counterparts with long G1 phases. During the earliest stages of differentiation toward all lineages, MCM loading slowed concurrently with G1 lengthening, revealing developmental control of MCM loading. Rapid licensing in stem cells was caused by accumulation of the MCM loading protein, Cdt1 (DNA replication factor Cdt1). Prematurely slowing MCM loading in pluripotent cells not only lengthened G1 but also accelerated differentiation. Thus, rapid origin licensing was an intrinsic characteristic of stem cells that contributed to pluripotency maintenance.

"Studies like this help explain the underlying biology of rapidly dividing cells and may inform the development of future therapies, for example stem cell therapies or cancer treatments," said study senior author Dr. Jean Cook, professor of biochemistry and biophysics at the University of North Carolina. "We suspect that rapid MCM loading is an important aspect of how cancer cells manage to grow fast without excessively damaging their DNA. It is a target worth pursuing."

Related Links:
University of North Carolina

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more